Unraveling the IVIG mystique

Transfusion

Volumn 53, Issue 2, 2013, Pages 242-244

  Branch, Donald R ^a  

^a CANADIAN BLOOD SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE THROMBOCYTOPENIA; EDITORIAL; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOTHERAPY;

ADULT; ANTIGEN-ANTIBODY COMPLEX; CHILD; HISTORY, 20TH CENTURY; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 84873427882     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12053     Document Type: Editorial

References (30)

1. Eibl MM,. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008; 28: 737-764.
2. Schroeder HW Jr, Dougherty CJ,. Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients. Infection 2012; 40: 601-611.
3. Imbach P, Barandun S, Baumgartner C, Hirt A, Hofer F, Wagner HP,. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta 1981; 36: 81-86.
4. Imbach P, Barandnun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP,. High dose intravenous immunoglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1: 1228-1231.
5. Fehr J, Hofmann V, Kappeler U,. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gammaglobulin. N Engl J Med 1982; 306: 1254-1258.
6. Imbach P, Morell A,. Idiopathic thrombocytopenic purpura (ITP): immunomodulation by intravenous immunoglobulin (IVIg). Int Rev Immunol 1989; 5: 181-188.
7. Berkman SA, Lee ML, Gale RP,. Clinical uses of intravenous immunoglobulins. Semin Hematol 1988; 25: 140-158.
8. Schwartz SA,. Intravenous immunoglobulin (IVIG) for the therapy of autoimmune disorders. J Clin Immunol 1990; 10: 81-89.
9. Chipps E, Skinner C,. Intravenous immunoglobulin: implications for use in the neurological patient. J Neurosci Nurs 1994; 26: 8-17.
10. Foley-Nolan D, Gooi HC,. Current rheumatological uses of intravenous immunoglobulin. Br J Reheumatol 1994; 33: 1002-1006.
11. Branch DW, Porter TF, Paidas MJ, Belfort MA, Gonik B,. Obstetric uses of intravenous immunoglobulin: successes, failures, and promises. J Allergy Clin Immunol 2001; 108: S133-138.
12. Jolles S, Hughes J, Whittaker S,. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 1998; 134: 80-86.
13. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA,. Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA 1995; 273: 1865-1870.
14. Wallington T,. New uses for IVIgG immunoglobulin therapies. Vox Sang 2004; 87 (Suppl. 2): 155-157.
15. Jolles S, Sewell WA, Misbah SA,. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005; 142: 1-11.
16. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP Jr, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C,; Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006; 117 (Suppl.): S525-553.
17. Fernandez AP, Kerdel FA,. The use of i.v. IG therapy in dermatology. Dermatol Ther 2007; 20: 288-305.
18. Leong H, Stachnik J, Bonk ME, Matuszewski KA,. Unlabeled uses of intravenous immune globulin. Am J Health Syst Pharm 2008; 65: 1815-1824.
19. Spurlock NK, Prittie JE,. A review of current indications, adverse effects, and administration recommendations for intravenous immunoglobulin. J Vet Emerg. Crit Care 2011; 21: 471-483.
20. Augener W, Friedmann B, Brittinger G,. Are aggregates of IgG the effective part of high-dose immunoglobulin therapy in adult idiopathic thrombocytopenic purpura (ITP)? Blut 1985; 50: 249-252.
21. Teeling JL, Jansen-Hendriks T, Kuijpers TW, de, Haas M, van de, Winkel JG, Hack CE, Bleeker WK,. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001; 98: 1095-1099.
22. Vassilev TL, Bineva IL, Dietrich G, Kaveri SV, Kazatchkine MD,. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J Autoimmun 1995; 8: 405-413.
23. Berger M,. L-proline-stablized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use. Immunotherapy 2011; 3: 163-176.
24. Tremblay T, Paré I, Bazin R,. Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia. Transfusion 2013; 53: 261-269.
25. Leontyev D, Katsman Y, Branch DR,. Mouse Background and IVIG dosage are critical in establishing the role of inhibitory Fc receptor for the amelioration of experimental ITP. Blood 2012; 119: 5261-5264.
26. Lamoureux J, Aubin E, Lemieux R,. Autoantibodies purified from therapeutic preparations of intravenous immunoglobulins (IVIg) induce the formation of autoimmune complexes in normal human serum: a role in the in vivo mechanism of action of IVIg? Int Immunol 2004; 16: 929-936.
27. Siragam V, Brinc D, Crow AR, Song S, Freedman J, Lazarus AH,. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest 2005; 115: 155-160.
28. Bazin R, Lemieux R, Tremblay T, St-Amour I,. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo pahocytosis of blood cells. Br J Haematol 2004; 127: 90-96.
29. Bazin R, Lemieux R, Tremblay T,. Reversal of immune thrombocytopenia in mice by cross-linking human immunoglobulin G with a high-affinity monoclonal antibody. Br J Haematol 2006; 135: 97-100.
30. Popper K,. The logic of scientific discovery. New York: Routledge; 2004.